Asbell P A
Department of Ophthalmology, Mount Sinai School of Medicine and the Mount Sinai Hospital of Mount Sinai NYU Health, New York, 10029-6574, USA.
J Cataract Refract Surg. 2001 Sep;27(9):1456-68. doi: 10.1016/s0886-3350(01)00980-4.
To evaluate the long-term visual results in patients having Intacs placement for the correction of mild myopia.
Department of Ophthalmology, Mount Sinai School of Medicine and the Mount Sinai Hospital of Mount Sinai NYU Health, New York, New York, USA.
Patients with mild myopia (spherical equivalent between -0.75 and -4.50 diopters [D]) were enrolled to have Intacs placement between May 1995 and March 1999 under United States Food and Drug Administration Phase II and Phase III clinical trials for intrastromal corneal ring segments (ICRS). Six insert thicknesses were evaluated: 0.21, 0.25, 0.30, 0.35, 0.40, and 0.45 mm. The long-term results evaluated were uncorrected visual acuity (UCVA), maintenance of best spectacle-corrected visual acuity (BSCVA), predictability and stability of the refractive effect, induced manifest refraction cylinder, slitlamp findings, self-reported visual symptoms, and maintenance of mesopic contrast sensitivity.
One hundred fourteen eyes of 73 patients were enrolled; 113 eyes of 72 patients received Intacs. There were no serious intraoperative or postoperative complications. The mean follow-up was 17.5 months +/- 8.9 (SD). At the end of this period (number of eyes evaluated = 100), the UCVA was 20/40 or better in 95 eyes (95.0%), 20/20 or better in 72 (72%), and 20/16 or better in 41 (41%). None of the 113 eyes lost 10 or more letters or 2 or more lines of preoperative BSCVA. The mean change in the cycloplegic refraction spherical equivalent for the 6 insert thicknesses was as follows: -0.75 +/- 0.00 D for 0.21 mm; -1.17 +/- 0.42 D for 0.25 mm; -2.00 +/- 0.54 D for 0.30 mm; -2.59 +/- 0.53 D for 0.35 mm; -3.09 +/- 0.54 D for 0.40 mm; and -3.82+/-0.80 D for 0.45 mm. The refractive correction was within +/-1.0 D of the predicted outcome in 103 eyes (92.0%) and within +/-0.5 D in 72 eyes (63.7%). Intacs were removed from 6 eyes (5.3%). All 4 eyes for which data were available 3 months after removal returned to within +/-0.5 D of their preoperative manifest refraction spherical equivalent. Intacs were exchanged because of undercorrection in 2 eyes (1.8%). These eyes gained 3 and 5 lines of UCVA 12 months and 18 months, respectively, after the exchange procedure. Overall, 85.7% (36/42) of the patients were satisfied with the results of the Intacs procedure.
Intacs safely and effectively corrected mild myopia. Placement is a brief, easy outpatient procedure. The refractive effect was predictable and stable over long-term follow-up. Results from a limited number of removal and exchange procedures indicate that Intacs are removable and adjustable.
评估接受Intacs植入术矫正轻度近视患者的长期视力结果。
美国纽约西奈山医学院眼科以及西奈山纽约大学健康中心西奈山医院。
1995年5月至1999年3月期间,纳入轻度近视患者(等效球镜度数在-0.75至-4.50屈光度[D]之间),在美国食品药品监督管理局针对角膜基质环段(ICRS)的II期和III期临床试验中接受Intacs植入术。评估了六种植入厚度:0.21、0.25、0.30、0.35、0.40和0.45毫米。评估的长期结果包括未矫正视力(UCVA)、最佳矫正视力(BSCVA)的维持情况、屈光效果的可预测性和稳定性、诱导的显性验光柱镜、裂隙灯检查结果、自我报告的视觉症状以及中间视觉对比敏感度的维持情况。
73例患者的114只眼纳入研究;72例患者的113只眼接受了Intacs植入。术中及术后均无严重并发症。平均随访时间为17.5个月±8.9(标准差)。在此期间结束时(评估眼数 = 100),95只眼(95.0%)的UCVA为20/40或更好,72只眼(72%)为20/20或更好,41只眼(41%)为20/16或更好。113只眼中没有一只眼的术前BSCVA下降10个或更多字母或2行或更多行。六种植入厚度的睫状肌麻痹验光等效球镜平均变化如下:0.21毫米为-0.75±0.00 D;0.25毫米为-1.17±0.42 D;0.30毫米为-2.00±0.54 D;0.35毫米为-2.59±0.53 D;0.40毫米为-3.09±0.54 D;0.45毫米为-3.82±0.80 D。103只眼(92.0%)的屈光矫正结果在预测结果的±1.0 D范围内,72只眼(63.7%)在±0.5 D范围内。6只眼(5.3%)取出了Intacs。取出后3个月有数据的4只眼中,所有眼均恢复到术前显性验光等效球镜的±0.5 D范围内。2只眼(1.8%)因矫正不足更换了Intacs。更换手术后,这两只眼分别在12个月和18个月时UCVA提高了3行和5行。总体而言,85.7%(36/42)的患者对Intacs手术结果满意。
Intacs安全有效地矫正了轻度近视。植入术是一种简短、简便的门诊手术。屈光效果在长期随访中具有可预测性和稳定性。有限数量的取出和更换手术结果表明Intacs是可取出和可调节的。